<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CICLOPIROX OLAMINE</span><br/>(sye-kloe-peer'ox)<br/><span class="topboxtradename">Loprox, </span><span class="topboxtradename">Penlac Nail Lacquer<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antifungal antibiotic</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1% cream, ointment; 8% nail lacquer; 1% shampoo</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic broad-spectrum antifungal agent with activity against pathogenic fungi. Inhibits transport of amino acids within
         fungal cell, thereby interfering with synthesis of fungal protein, RNA, and DNA.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against the following organisms: dermatophytes, yeasts, and <i>Malassezia furfur,</i> some species of <i>Mycoplasma</i> and <i>Trichomonas vaginalis,</i> and certain strains of gram-positive and gram-negative bacteria.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Topically for treatment of tinea cruris and tinea corporis (ringworm) due to <i>Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum,</i> and <i>Microsporum canis,</i> and for tinea (pityriasis) versicolor due to <i>M. furfur;</i> also cutaneous candidiasis (moniliasis) caused by <i>Candida albicans.</i> Nail lacquer indicated for onychomycosis of fingernails and toenails due to <i>T. rubrum;</i> seborrheic dermatitis of the scalp.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ciclopirox olamine or to any component in the formulation; pregnancy (category B). Safe use in children
         
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation; type 1 diabetic patient.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Tinea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Massage cream into affected area and surrounding skin twice daily, morning and evening.<br/><br/><span class="indicationtitle">Onychomycosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Paint affected nail(s) under the surface of the nail and on the nail bed once daily at bedtime (at least 8 h before washing).
               After 7 d, remove lacquer with alcohol and remove or trim away unattached nail. Continue up to 48 wk.<br/><br/><span class="indicationtitle">Seborrheic Dermatitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Wet hair and apply approximately 1 tsp (5 mL) to the scalp (may use up to 10 mL for long hair), leave on scalp for 3 min,
               then rinse. Repeat treatment twice/wk <small>x</small> 4 wk, with a min 3 d between applications.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Wash hands thoroughly before and after treatments.</li>
<li>Consult with physician about specific procedure for cleansing the skin before medication is applied. Regardless of method
            used, dry skin thoroughly before drug application.
         </li>
<li>Avoid occlusive dressing, wrapping, or clothing over site where cream is applied.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Skin:</span> Irritation, pruritus, burning, worsening of clinical condition. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 1.3% absorbed through intact skin. <span class="typehead">Distribution:</span> Distributed to epidermis, corium (dermis), including hair and hair follicles and sebaceous glands; not known if crosses placenta
      or is distributed into breast milk. <span class="typehead">Elimination:</span> Excreted primarily by kidneys. <span class="typehead">Half-Life:</span> 1.7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness. Tinea versicolor generally responds to drug treatment in about 2 wk. Tinea pedis ("athlete's
            foot"), tinea corporis (ringworm), tinea cruris ("jock itch"), and candidiasis (moniliasis) require about 4 wk
            of therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use medication for the prescribed time even though symptoms improve.</li>
<li>Report skin irritation or other possible signs of sensitization. A reaction suggestive of sensitization warrants drug discontinuation.</li>
<li>Do not use occlusive dressings or wrappings.</li>
<li>Avoid contact of drug in or near the eyes.</li>
<li>Wear light clothing and footwear that will allow ventilation. Loose-fitting cotton underwear or socks are preferred.</li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>